Purchase this article with an account.
Eiko Tsuiki, Kiyoshi Suzuma, Yasser Helmy Mohamed, Yoshihisa Yamada, MAKIKO MATSUMOTO, Takashi Kitaoka; Oral kalliginogenase improved chorioretinal blood flow levels and significantly reduced subfoveal choroidal thickness in diabetic macular edema patients.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3260.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We investigated the effect of oral kallidinogenase on chorioretinal blood flow and subfoveal choroidal thickness (SCT) in diabetic macular edema (DME) patients who underwent focal laser and sub-Tenon injection of triamcinolone acetonide for clinically significant macular edema.
In this prospective, randomized clinical study (UMIN000005339), best corrected visual acuity (BCVA), SCT and chorioretinal blood flow level were measured in 21 patients (22 eyes) at the Department of Ophthalmology & Visual Sciences, Nagasaki University. Chorioretinal blood flow levels at the macula were measured by LSFG-NAVITM (Softcare, Fukuoka, Japan) and evaluated using the mean blur rate (MBR). These were measured at baseline and at 1, 3, and 6 months after treatment initiation.
Twelve eyes were assigned to a kallidinogenase-treated group and 10 eyes were assigned to an untreated group. Compared to baseline (100%), MBR at the macula of 6 months after treatment significantly decreased to 86.2±17.2 % in untreated group (P<0.05), though it has maintained 100.7±15.2% in patients in kallidinogenase-treated group. The mean SCT at baseline was 298.1±75.0 μm (with kalliginogenase) and 292.1±101.6 μm (without kalliginogenase), there was no significant difference between two groups. The mean SCT after treatment in kalliginogenase-treated group was 269.8±68.1μm (1 month), 283.7±75.7μm (3 months) and 287.1±75.3μm (6 months) respectively, which was significantly thinner than that before treatment (P<0.01). BCVA at 6 months after treatment significantly improved in kallidinogenase-treated group (P<0.05). Both of SCT and BCVA exhibited no statistically significant difference during 6 months after treatment in untreated group.
Kallidinogenase is able to improve chorioretinal blood flow levels and significantly reduced SCT in DME patients.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only